Literature DB >> 24973422

Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Dennis L Stevens1, Alan L Bisno2, Henry F Chambers3, E Patchen Dellinger4, Ellie J C Goldstein5, Sherwood L Gorbach6, Jan V Hirschmann7, Sheldon L Kaplan8, Jose G Montoya9, James C Wade10.   

Abstract

A panel of national experts was convened by the Infectious Diseases Society of America (IDSA) to update the 2005 guidelines for the treatment of skin and soft tissue infections (SSTIs). The panel's recommendations were developed to be concordant with the recently published IDSA guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections. The focus of this guideline is the diagnosis and appropriate treatment of diverse SSTIs ranging from minor superficial infections to life-threatening infections such as necrotizing fasciitis. In addition, because of an increasing number of immunocompromised hosts worldwide, the guideline addresses the wide array of SSTIs that occur in this population. These guidelines emphasize the importance of clinical skills in promptly diagnosing SSTIs, identifying the pathogen, and administering effective treatments in a timely fashion.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2014        PMID: 24973422     DOI: 10.1093/cid/ciu444

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  365 in total

1.  Ciprofloxacin: Tularemia (Adults).

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2015-04-08

Review 2.  Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

Authors:  Lizanne Béïque; Rosemary Zvonar
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

3.  Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.

Authors:  Felipe F Rodrigues; Marcela I Morais; Ivo S F Melo; Paulo S A Augusto; Marcela M G B Dutra; Sarah O A M Costa; Fábio C Costa; Franciele A Goulart; Alysson V Braga; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-11-25       Impact factor: 4.473

4.  Guideline-concordant antibiotic prescribing for pediatric outpatients with otitis media, community-acquired pneumonia, and skin and soft tissue infections in a large multispecialty healthcare system.

Authors:  Ezzeldin A Saleh; Darrell R Schroeder; Andrew C Hanson; Ritu Banerjee
Journal:  Clin Res Infect Dis       Date:  2015-01-10

5.  Diagnosis and management of cellulitis.

Authors:  Tadhg Sullivan; Eoghan de Barra
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

6.  Evaluation of Oritavancin Use at a Community Hospital.

Authors:  Daniel Co; Leslie Roebuck; Jason VanLandingham
Journal:  Hosp Pharm       Date:  2017-12-04

7. 

Authors:  María José Monedero Mira; Manuel Batalla Sales; Concepción García Domingo; María José Monedero Mira; Belén Persiva Saura; Gloria Rabanaque Mallen; Lledó Tárrega Porcar
Journal:  FMC       Date:  2016-04-26

8.  A Tick Antivirulence Protein Potentiates Antibiotics against Staphylococcus aureus.

Authors:  Nabil M Abraham; Lei Liu; Brandon L Jutras; Kristen Murfin; Ali Acar; Timur O Yarovinsky; Erica Sutton; Martin Heisig; Christine Jacobs-Wagner; Erol Fikrig
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 9.  Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review.

Authors:  Jason P Burnham; John P Kirby; Marin H Kollef
Journal:  Intensive Care Med       Date:  2016-10-03       Impact factor: 17.440

Review 10.  Pharmacologic and clinical evaluation of posaconazole.

Authors:  Jason N Moore; Jason R Healy; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2015-05       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.